Haplotype Distribution in All Patients and by Treatment Group
| Variable . | Total MSH Group . | Comparison Group* . | HU MSH Group . | Placebo MSH Group . |
|---|---|---|---|---|
| . | (n = 295) . | (n = 468) . | (n = 143) . | (n = 135) . |
| Mean age (yr) | 30.5 | 31 | 31 | 30 |
| BEN/BEN | 40 | 33 | 37 | 44 |
| BEN/CAR | 21 | 22 | 21 | 21 |
| BEN/SEN | 12 | 13 | 13 | 12 |
| SEN/SEN | <1 | 4 | — | — |
| SEN/CAR | 3 | 6 | 3 | 3 |
| CAR/CAR | 3 | 4 | 3 | 3 |
| Other† | 20 | 18 | 23 | 17 |
| Variable . | Total MSH Group . | Comparison Group* . | HU MSH Group . | Placebo MSH Group . |
|---|---|---|---|---|
| . | (n = 295) . | (n = 468) . | (n = 143) . | (n = 135) . |
| Mean age (yr) | 30.5 | 31 | 31 | 30 |
| BEN/BEN | 40 | 33 | 37 | 44 |
| BEN/CAR | 21 | 22 | 21 | 21 |
| BEN/SEN | 12 | 13 | 13 | 12 |
| SEN/SEN | <1 | 4 | — | — |
| SEN/CAR | 3 | 6 | 3 | 3 |
| CAR/CAR | 3 | 4 | 3 | 3 |
| Other† | 20 | 18 | 23 | 17 |
The percentage of patients with a given haplotype is shown.
The comparison group is a study of 468 patients with HbSS who were regular attenders of their respective clinics in the urban northeast and semirural south.3
Other includes patients heterozygous or homozygous for atypical and Cameroon haplotypes.